Surotomycin versus vancomycin forClostridium difficileinfection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial | Zendy

Christine H. Lee | Zendy; Hernando Patino | Zendy; Chris Stevens | Zendy; Shruta Rege | Zendy; Laurent Chesnel | Zendy; Thomas Louie | Zendy; Kathleen M. Mullane | Zendy

Open Access

Surotomycin versus vancomycin forClostridium difficileinfection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial

Author(s) -

Christine H. Lee,

Hernando Patino,

Chris Stevens,

Shruta Rege,

Laurent Chesnel,

Thomas Louie,

Kathleen M. Mullane

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw246

Subject(s) - medicine , vancomycin , clostridium difficile , adverse effect , antibiotics , randomized controlled trial , incidence (geometry) , clinical trial , surgery , diarrhea , antibacterial agent , gastroenterology , anesthesia , staphylococcus aureus , microbiology and biotechnology , physics , optics , biology , bacteria , genetics

Clostridium difficile infection (CDI) is a major public health concern. Treatment with commonly prescribed antibiotics is associated with high rates of recurrence after initial cure. Here, we present the efficacy and safety of surotomycin, an orally administered, minimally absorbed, selective bactericidal cyclic lipopeptide, compared with vancomycin, in patients with CDI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research